Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK)
US-9115122-B2 · Aug 25, 2015 · US
Inhibitors of extracellular signal-regulated kinase
US2025129038A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025129038-A1 |
| Application number | US-202418920501-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 18, 2024 |
| Priority date | Oct 18, 2023 |
| Publication date | Apr 24, 2025 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The compound 1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate, pharmaceutical compositions thereof, and use of the compound and the pharmaceutical compositions for treating cancer and pulmonary diseases are disclosed.
First claim
Opening claim text (preview).
1 . The compound 1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate having the structure of Formula (1): or a pharmaceutically acceptable salt thereof. 2 . The compound of claim 1 , wherein the compound is (S)-1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate (1a): or a pharmaceutically acceptable salt thereof. 3 . The compound of claim 1 , wherein the compound is (R)-1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate (1b): or a pharmaceutically acceptable salt thereof. 4 . The compound of claim 1 , wherein the compound is the free base. 5 . The compound of claim 1 , wherein the compound is the hydrochloric acid salt. 6 . A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof. 7 . A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the disease is treated by inhibiting extracellular signal-regulated kinase 1 and/or extracellular signal-regulated kinase 2. 8 . A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the disease is selected from cancer, an inflammatory disease, an autoimmune disease, or a pulmonary disease. 9 . A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 6 , wherein the disease is treated by inhibiting extracellular signal-regulated kinase 1 and/or extracellular signal-regulated kinase 2. 10 . A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 6 , wherein the disease is selected from cancer, an inflammatory disease, an autoimmune disease, or a pulmonary disease. 11 . The compound of claim 2 , wherein the compound is the free base. 12 . The compound of claim 2 , wherein the compound is the hydrochloric acid salt. 13 . A pharmaceutical composition comprising the compound of claim 2 or a pharmaceutically acceptable salt thereof. 14 . A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein the disease is selected from cancer, an inflammatory disease, an autoimmune disease, or a pulmonary disease. 15 . A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 13 , wherein the disease is selected from cancer, an inflammatory disease, an autoimmune disease, or a pulmonary disease. 16 . The compound of claim 3 , wherein the compound is the free base. 17 . The compound of claim 3 , wherein the compound is the hydrochloric acid salt. 18 . A pharmaceutical composition comprising the compound of claim 3 or a pharmaceutically acceptable salt thereof. 19 . A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein the disease is selected from cancer, an inflammatory disease, an autoimmune disease, or a pulmonary disease. 20 . A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 18 , wherein the disease is selected from cancer, an inflammatory disease, an autoimmune disease, or a pulmonary disease.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
- C07D333/48Primary
by oxygen atoms · CPC title
having five-membered rings · CPC title
Drugs for disorders of the respiratory system · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2025129038A1 cover?
- The compound 1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate, pharmaceutical compositions thereof, and use of the compound and the pharmaceutical compositions for treating cancer and pulmonary diseases are disclosed.
- Who is the assignee on this patent?
- Gen1E Lifesciences Inc, Univ Maryland
- What technology area does this patent fall under?
- Primary CPC classification C07D333/48. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Apr 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).